Glypican-3
Glypican-3 is a fetal liver protein that reappears in liver cancer, giving CAR-T and bispecifics a clean target.
GPC3 is expressed in ~70% of hepatocellular carcinoma and essentially absent from normal adult liver. Antibodies failed as monotherapy (codrituzumab), but GPC3 CAR-T (including armoured constructs from AstraZeneca/Neogene and Chinese groups) and GPC3×CD3 bispecifics are showing responses.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · Glypican-3 is a fetal liver protein that reappears in liver cancer, giving CAR-T and bispecifics a clean target.
- 1 · What it is
Glypican-3 is a fetal liver protein that reappears in liver cancer, giving CAR-T and bispecifics a clean target.
- 2 · What goes wrong in cancer
Glypican-3 is a heparan sulfate proteoglycan modulating Wnt and Hedgehog signalling.
- 3 · How drugs use it
No product in this corpus aims at Glypican-3 yet. Because it sits on the outside of the cell, it can be reached from the bloodstream: antibodies flag the cell, ADCs deliver a toxin, radioligands deliver radiation, and CAR-T or bispecifics bring a T cell.
Biology
Glypican-3 is a heparan sulfate proteoglycan modulating Wnt and Hedgehog signalling.
- Hepatocellular carcinoma
- Hepatoblastoma
- Yolk-sac tumours
How common it is, by cancer
| Cancer | Prevalence | Measure | Note | Source |
|---|---|---|---|---|
| Hepatocellular carcinoma | 70-80% | IHC, any expression | Wikipedia |
Approximate, population-level figures; the measure column says what was counted. Ranges show the midpoint as a bar.
Latest papers
topQuery for this target: (TITLE:"Glypican-3" OR ABSTRACT:"Glypican-3" OR TITLE:"GPC3" OR ABSTRACT:"GPC3") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Glypican-3, not a curated reading list.
Pages like this
not linked directly; found by shared links- TargetCD70
Shares CAR-T cell therapy and the tag car-t-target.
- TargetCD19
Shares CAR-T cell therapy and the tag car-t-target.
- TargetClaudin 18.2
Shares In vivo CAR-T against solid-tumour antigens, Cell therapy roadmap: CD19 CAR-T → solid tumours → in vivo CAR, CAR-T cell therapy and the tag car-t-target.
- TargetMesothelin
Shares CAR-T cell therapy and the tag car-t-target.
- TargetBCMA
Shares CAR-T cell therapy and the tag car-t-target.
- ProductSatricabtagene autoleucel
Shares In vivo CAR-T against solid-tumour antigens, Cell therapy roadmap: CD19 CAR-T → solid tumours → in vivo CAR, CAR-T cell therapy.
- IdeaIn vivo CAR-T as a vial on the shelf: a cost and access trial in lymphoma
Shares In vivo CAR-T against solid-tumour antigens, CAR-T cell therapy.
- InstitutionTaipei Veterans General Hospital